Navegar por autor "Chaparro, M."

Mostrando ítems 1-6 de 6

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

2019- Chaparro, M.; Donday, M. G.; Barreiro de Acosta, Manuel; Domènech, E.; Esteve, M.; [et al.]
Effectiveness and Safety of the Switch from Remicade (R) to CT-P13 in Patients with Inflammatory Bowel Disease

2019- De Castro Parga, María Luisa; Chaparro, M.; Garre, A.; Veloz, M. F. G.; Moron, J. M. V.; [et al.]
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

2019- Chaparro, M.; Barreiro de Acosta, Manuel; Benítez, J. M.; Casanova, M. J.; Ceballos, D.; [et al.]
Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU

2019- Chaparro, M.; Barreiro de Acosta, Manuel; Benitez, J.; Cabriada, J.; Casanova, M.; [et al.]
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease

2019- Chaparro, M.; Aterido, A.; Guerra, I.; Iborra, M.; Cabriada, J. L.; [et al.]
Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con enfermedad inflamatoria intestinal asociada a espondiloartritis

2020- González-Lama, Y.; Sanz, J.; Bastida, G.; Campos, J.; Ferreiro Iglesias, Rocio; [et al.]